Why transduction enhancers matter in manufacturing
Primary T cells, NK cells, and iPSCs are inherently resistant to viral vector entry because of rigid plasma membranes, low surface receptor expression, and endogenous antiviral mechanisms. Without an effective enhancer, teams compensate with higher multiplicity of infection (MOI), which drives up vector consumption — the single largest cost driver in cell therapy manufacturing — and simultaneously raises vector copy number (VCN), increasing genotoxic risk.
An ideal enhancer therefore has to do four things at once: achieve high transduction efficiency at low MOI, preserve cell viability, keep VCN below clinical-grade safety thresholds, and integrate with closed, automated manufacturing — the exact combination flagged as the current unmet need in the HiTE™ Technology White Paper.
Short profiles of each enhancer category
The comparisons below are limited to what is documented in the HiTE™ internal benchmarking. They are not a market-wide review.
HiTE™ (Transient Fusion-Promoting Peptide)
HiTE™ is a bi-functional synthetic peptide that binds both lentiviral envelope proteins and target cell membrane receptors, promoting virus–cell proximity and transient, controlled membrane fusion, then self-inactivating within hours. It is supplied as a 400 µM stock, used at 20–160 µM depending on cell type, with no plate coating and no required spinoculation. HiTE™ is classified as "For Research Use Only. Not for diagnostic or therapeutic use."
Retronectin (recombinant fibronectin fragment)
In the white paper's head-to-head platform comparison, retronectin-based workflows are represented by the gold-standard spinoculation protocol: plate coating (2–4 hours or overnight), BSA blocking, virus loading, cell loading, 90-minute spinoculation at 1,000×g, overnight incubation, and a media change — more than 24 hours of multi-step, open-system handling. Reported transduction efficiency in this comparison is approximately 15 % in T cells and ~20 % in iPSCs, with viability of 70–80 % and NK cell efficiency described as "Limited."
Polybrene (hexadimethrine bromide)
Polybrene is a cationic polymer that broadly destabilizes membranes without temporal control. In the white paper benchmark, Polybrene yields 8.0 % efficiency in T cells, 16.8 % in iPSCs, and 6.0 % efficiency in NK cells — but the NK result is marked with an important caveat: Polybrene reduces NK cell viability to approximately 17 % (vs. a >80 % baseline). This eliminates any transduction benefit and is described as clinically unsuitable for NK cells; the NK protocol explicitly states "Do not use Polybrene for NK cell transduction." The iPSC protocol notes that Polybrene can also trigger spontaneous differentiation and loss of OCT4/NANOG in iPSCs and advises against its use in that cell type as well.
LentiBOOST
In the same internal benchmark, LentiBOOST reports 15.3 % transduction efficiency in T cells, 23.7 % in iPSCs, and 0.7 % in NK cells, with viability of 88.6 %.
No enhancer (virus only)
Baseline performance without an enhancer was 7.2 % in T cells, 21.2 % in iPSCs, and 0.8 % in NK cells, with viability of 90.0 % in the T cell assay.
Side-by-side comparison
All values below are drawn from the HiTE™ Technology White Paper figures and tables, generated with CD19-CAR lentiviral constructs at Day 3 post-transduction, n=3 independent biological replicates, with significance reported at ****p<0.0001 where indicated.
Transduction efficiency across cell types
| Enhancer | CD3+ T cells | iPSCs | NK cells |
|---|---|---|---|
| No enhancer | 7.2 % | 21.2 % | 0.8 % |
| Polybrene | 8.0 % | 16.8 % | 6.0 % (viability compromised) |
| LentiBOOST | 15.3 % | 23.7 % | 0.7 % |
| Retronectin | ~15 % | ~20 % | Limited |
| HiTE™ | 63.0 % | 73.9 % | 33.3 % |
Fold improvements of HiTE™ over each comparator in the same benchmark are 8.75× (T cells), 3.6× (iPSCs), and 1.52× (NK cells) versus no enhancer; 7.9× / 4.4× / 2.04× versus Polybrene; and 4.1× / 3.1× / 1.35× versus LentiBOOST. The white paper also describes HiTE™ as achieving a 47.6-fold improvement in NK cells over the best-performing alternative, excluding the unusable Polybrene condition.
Cell viability
| Condition | Viability (Day 3) |
|---|---|
| Untransduced control | 97.6 % |
| No enhancer + virus | 90.0 % |
| HiTE™ + virus | 90.2 % |
| LentiBOOST + virus | 88.6 % |
| Polybrene + virus | 53.8 % |
HiTE™ viability is statistically equivalent to untransduced controls; Polybrene falls well below the >90 % viability bar described as an ideal-enhancer criterion.
Vector copy number and the FDA-guided safety threshold
Regulatory guidance referenced in the white paper recommends maintaining VCN below 5 copies per cell for clinical-grade gene-modified cell products. Because HiTE™ delivers high efficiency at low MOI, it produces a mean VCN of 2.8 ± 0.1 copies per cell — below the threshold. Polybrene at the same MOI yields a mean VCN of 7.0 ± 0.3, exceeding the threshold by roughly 40 %.
Workflow, automation, and platform compatibility
From the head-to-head platform comparison in the white paper:
| Parameter | HiTE™ | Retronectin | Polybrene | LentiBOOST |
|---|---|---|---|---|
| Workflow time | <1 hour core hands-on (<8 hours total) | >24 hours | <1 hour | <1 hour |
| Spinoculation required | No | Yes | Optional | Optional |
| Plate coating required | No | Yes | No | No |
| Self-inactivating | Yes | No | No | No |
| Automation compatible | Yes | No | Partial | Yes |
The traditional retronectin-based protocol involves plate coating (2–4 hours or overnight), BSA blocking, virus loading, cell loading onto coated plates, spinoculation (1,000×g, 90 minutes), overnight incubation, and a media change — a ≥24-hour, multi-step, open-system process. The HiTE™ protocol, by contrast, consists of adding cells to standard plates, adding HiTE™ plus viral vector, mixing gently, and incubating, with an optional media change — completed in under 8 hours and compatible with closed-system automation.
Manufacturing and safety implications
Lower MOI, less vector, more predictable economics
Viral vector production represents the dominant cost driver in cell therapy manufacturing, often accounting for 50–70 % of total cost of goods (COGS). Because HiTE™ enables equivalent or superior transduction at 5–10× lower MOI, it directly reduces vector consumption per dose. The white paper provides a representative internal cost model (explicitly labeled as dependent on vector type, MOI, and manufacturing scale):
| Cost component | Traditional | With HiTE™ |
|---|---|---|
| Viral vector cost/dose | $25,000–$50,000 | $5,000–$10,000 |
| Vector usage | Baseline | 5–10× reduction |
| Total COGS per dose | $95,000–$120,000 | $60,000–$80,000 |
| Cost savings | — | 33–50 % (representative) |
These numbers are representative internal modeling for a specific scenario, not market-wide price guarantees. Actual savings will vary by vector type, MOI, and manufacturing scale.
Why VCN and viability matter for lot release
High transduction efficiency at high MOI often pushes VCN above the 5-copies-per-cell threshold referenced by the FDA and EMA, introducing insertional mutagenesis risk and raising the probability of a failed lot release. HiTE™'s combination of a mean VCN of 2.8 and >90 % Day-3 viability across donors positions it to support reliable lot release from a manufacturing-metric standpoint, within the research-use context of the documented data.
Workflow, contamination risk, and automation
Retronectin's 24+ hour open-system workflow creates repeated operator touchpoints and sterility risk. HiTE™'s direct-addition workflow, with no plate coating, no spinoculation, and no overnight step, integrates with closed automated manufacturing systems including the Miltenyi CliniMACS Prodigy and Lonza Cocoon platforms via direct addition to tubing sets. Internal benchmarking described in the white paper reports a 2.17-fold increase in successful manufacturing run yield and a 92 % reduction in total workflow time versus 24-hour traditional protocols.
When HiTE™ is particularly advantageous
Based on the internal benchmarking above, HiTE™ is most clearly differentiated from conventional enhancers when:
- The target cell type is hard to transduce — primary CD3+ T cells, primary NK cells, and iPSCs — and the team needs both high efficiency and preserved viability, not one at the expense of the other.
- Vector budget is a constraint and the process is aiming for a 5–10× MOI reduction relative to the traditional workflow.
- VCN control is critical for lot release and the program cannot accept the elevated VCN seen with Polybrene at equivalent MOI.
- The process needs to fit a closed, automation-compatible workflow on CliniMACS Prodigy or Lonza Cocoon platforms without plate coating or spinoculation.
All data shown are internal benchmarking from PyrOjas, generated with CD19-CAR lentiviral constructs at Day 3 post-transduction, and are intended for research use only. HiTE™ is classified as "For Research Use Only. Not for diagnostic or therapeutic use."